Loading
Veracyte, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Jun 2022.
Veracyte, Inc.: what insiders have been doing
Veracyte, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 20 insiders have disclosed 77 filings since 18 October 2025.
No insider bought on the market over the period, while 11 insiders filed 27 sales totalling €4.5M. No amount is published for 2 filings, which the totals therefore leave out. Biggest ticket of the year: €589k, sold by Stapley Marc and made public on 6 March 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 77 filings in twelve months, the company is more active than the median of 19 filings across the 5,812 companies we follow on the same exchange. Since 2021, the database holds 2 purchases and 75 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 517.1 m USD and net income at 66.4 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
305
Thresholds
n/a
Buy Volume
€980,959
2 ops. · all time
Sell Volume
€15M
75 ops. · all time
Who traded when
BuySaleAnnie McGuire10 sales
Rebecca Chambers8 sales
John Leite5 sales
Karin Eastham5 sales
Phillip G. Febbo5 sales
Marc Stapley4 sales
+5 other insiders
Since the insiders bought
- -50.3%Entry US$34.94 · Close at T+365 US$17.36
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Veracyte, Inc. Buy (bullish), based on 12 analysts. Average price target: US$58.42.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 10,146 of 24,166 companies
55.7
score / 100
Value36
Quality75
FCF yld3.7%
Earn yld1.9%
EV/EBITDA39.1x
ROE8.8%
Gross mgn70%
Net mgn13%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$43.51
Analyst consensus
12 analystsBuy
US$44.00Target US$58.42(+34%)US$70.00
Income statement
RevenueUS$517.1M
Gross profitUS$362.5M70% margin
EBITDAUS$89.6M17% margin
Net incomeUS$66.4M20.4% margin
Valuation
PER (trailing)31.1x
PER (forward)22.4x
P/Book2.5x
Beta1.95
Balance sheet & cash
Market capUS$3.5B
Total debtUS$39.7M
Free Cash FlowUS$126.6M
Debt / Equity3%
Profitability & ownership
ROE8.8%
ROA4.1%
% insiders0.5%
% institutions114.8%
Last declaration on 24 September 2026
Declarations305 total
7,500 shares@ US$47.000.010% mcap63.7% of flowCommonSEC144:0001950047-26-009791
4,015 shares@ US$40.000.0045% mcap8.6% of flowCommon StockSEC:0001991536-26-000013:0
4,015 shares@ US$39.7950.0045% mcap100.0% of flowCommonSEC144:0001950047-26-009711
5,000 shares@ US$40.94940.0057% mcap32.6% of flowCommon StockSEC:0001819880-26-000004:0
5,000 shares@ US$40.94940.0057% mcap36.3% of flowCommonSEC144:0001950047-26-009444
3,652 shares@ US$44.670.0045% mcap100.0% of flowCommonSEC144:0001950047-26-009145
13,110 shares@ US$44.670.016% mcap100.0% of flowCommonSEC144:0001950047-26-009139
3,254 shares@ US$44.670.0040% mcap48.4% of flowCommonSEC144:0001950047-26-009146
2,477 shares@ US$42.80590.0029% mcap3.1% of flowCommon StockSEC:0001823563-26-000016:1
3,215 shares@ US$44.880.0040% mcap4.1% of flowCommon StockSEC:0001914620-26-000013:0
3,603 shares@ US$44.880.0045% mcap4.8% of flowCommon StockSEC:0001823563-26-000016:0
1,175 shares@ US$43.7140.0014% mcap1.5% of flowCommon StockSEC:0001823563-26-000016:2
3,639 shares@ US$44.880.0046% mcap6.8% of flowCommon StockSEC:0001649245-26-000009:0
10,405 shares@ US$42.89330.012% mcap18.5% of flowCommon StockSEC:0001649245-26-000009:1
2,705 shares@ US$43.66180.0033% mcap4.9% of flowCommon StockSEC:0001649245-26-000009:2
3,961 shares@ US$44.880.0050% mcap9.4% of flowCommon StockSEC:0001991536-26-000011:0
2,154 shares@ US$42.79160.0026% mcap2.6% of flowCommon StockSEC:0001914620-26-000013:1
1,100 shares@ US$43.67180.0013% mcap1.4% of flowCommon StockSEC:0001914620-26-000013:2
8,782 shares@ US$44.880.011% mcap5.9% of flowCommon StockSEC:0001539796-26-000019:0
1,361 shares@ US$44.880.0017% mcap5.0% of flowCommon StockSEC:0001584145-26-000009:0
1,864 shares@ US$42.970.0022% mcap15.2% of flowCommon StockSEC:0001846905-26-000006:0
3,200 sharesCommon StockSEC:0001231845-26-000006:0
529 sharesCommon StockSEC:0001231845-26-000006:1
3,729 shares@ US$51.29100.0% of flowCommonSEC144:0001950047-26-006311
5,272 sharesCommon StockSEC:0001940521-26-000002:0
25 of 305 declarations
About Veracyte, Inc.
Veracyte, Inc. (NYSE/NASDAQ: VCYT) is a U.S.-listed precision diagnostics company headquartered in South San Francisco, California, with additional offices in San Diego, Austin, Texas, and Haifa, Israel. The company was built around a clear clinical mission: improve cancer care by providing molecular answers that help clinicians avoid unnecessary invasive procedures and get patients to the right treatment faster. Veracyte describes itself as a global diagnostics company focused primarily on oncology and certain interstitial lung diseases, with an international operational footprint and a growing evidence base supporting clinical adoption. ([veracyte.com](https://www.veracyte.com/company/))
Veracyte’s business model is centered on a diagnostics platform that combines genomic and clinical data, bioinformatics, artificial intelligence, and evidence generation. This platform approach is important because it supports test performance, reimbursement durability, and guideline adoption. The company’s core commercial products include Afirma, which is widely associated with thyroid nodule assessment, and the Decipher franchise, a genomic classifier used prominently in prostate cancer and broader urologic oncology applications. Veracyte also highlights emerging pipeline and platform initiatives, including TrueMRD and planned Prosigna LDT-related launches, indicating continued investment in expanding its addressable market across the cancer care continuum. ([investor.veracyte.com](https://investor.veracyte.com/))
Read moreShow less
From a competitive standpoint, Veracyte differentiates itself through a high-value diagnostic niche: helping physicians make more confident decisions while reducing unnecessary procedures and associated costs. Rather than competing as a broad-based in vitro diagnostics vendor, the company has positioned itself as a leader in evidence-backed oncology diagnostics, where clinical utility, reimbursement, and physician trust are key barriers to entry. Management has also emphasized that growth is being driven primarily by Decipher and Afirma, underlining the importance of these franchises to the investment case. ([investor.veracyte.com](https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-fourth-quarter-and-full-year-2025-financial))
Recent developments have reinforced the growth narrative. In November 2025, Veracyte reported strong testing-revenue momentum and highlighted a Cell publication from the STAMPEDE trial showing that Decipher Prostate can predict chemotherapy benefit in metastatic prostate cancer, while also launching the Afirma v2 transcriptome to improve operational efficiency and serve as a platform for future products. In February 2026, the company reported full-year 2025 results, with strong double-digit growth in both Decipher and Afirma and more than 45,000 patients served with its core testing business in the quarter. These updates suggest a business that is scaling well while investing in its next wave of diagnostic innovation. ([investor.veracyte.com](https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-third-quarter-2025-financial-results))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
